Ceftazidime or gentamicin plus benzylpenicillin in neonates less than forty-eight hours old

Area of Science:

• Neonatal Medicine
• Infectious Diseases
• Pharmacology

Background:

• Neonatal sepsis presents a significant challenge in intensive care settings.
• Effective and safe antibiotic options are crucial for treating infections in newborns.
• Evaluating new antibiotic regimens is essential for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of ceftazidime as a first-line treatment for suspected sepsis in neonates.
• To compare ceftazidime with standard antibiotic regimens (penicillin and gentamicin).
• To assess the incidence of adverse events and secondary infections associated with ceftazidime use.

Main Methods:

• A randomized clinical trial involving 55 infants under 48 hours old with suspected sepsis.
• Infants were randomly assigned to receive either ceftazidime or penicillin and gentamicin.
• An open trial of ceftazidime was conducted in 22 infants older than 48 hours with clinical sepsis.
• Septic screens were performed before treatment; treatment was discontinued after 48 hours if cultures were sterile.

Main Results:

• Ceftazidime was effective in treating most cases of neonatal sepsis.
• Two cases of sepsis caused by group D beta-haemolytic streptococcus and coagulase-negative staphylococcus were resistant to ceftazidime, penicillin, and gentamicin.
• No adverse responses to ceftazidime were observed.
• The incidence of candidiasis was similar to that seen with other broad-spectrum antibiotics.
• Eliminating the need for gentamicin assays in the ceftazidime group offered a practical advantage.

Conclusions:

• Ceftazidime is an effective and safe first-line antibiotic option for neonatal sepsis.
• Its efficacy is comparable to standard treatments, with a favorable safety profile.
• The simplified monitoring requirements make ceftazidime a practical choice for neonatal intensive care.